论文部分内容阅读
目的观察中药复方苦参联合肝动脉化疗栓塞术TACE治疗原发性肝癌的疗效。方法将60例原发性肝癌患者原发性肝癌患者随机分为2组,实验组为复方苦参+TACE组,对照组为单纯TACE组,比较两组的近期疗效,1年生存率及毒副反应发生率。结果复方苦参+TACE组1年生存率高于对照组;肝功损伤,栓塞后综合征等毒副反应发生率低于对照组。结论复方苦参注射液联合TA-CE治疗原发性肝癌能够起到减毒增效的作用。
Objective To observe the curative effect of traditional Chinese medicine compound kushen combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods Sixty patients with primary hepatocellular carcinoma (HCC) were randomly divided into two groups. The experimental group was Compound Sophora flavescens + TACE group, while the control group was TACE group. The short-term curative effect, 1-year survival rate and toxicity The incidence of side effects. Results The 1-year survival rate of Compound Sophora flavescens + TACE group was higher than that of the control group. The incidence of liver toxicity and post-embolism syndrome was lower than that of the control group. Conclusion Compound Kushen injection combined with TA-CE treatment of primary liver cancer can play an attenuating and synergistic effect.